MedTrace Logo

The Effect of Chemotherapy on Regulatory T Cells

NCT03413046 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2018-01-29

No results posted yet for this study

Summary

The investigators aimed to study the effect of chemotherapy on regulatory T cells (Tregs) in children with precursor B (PreB) acute lymphoblastic leukemia (ALL) at 15 and 33 days of malignity directed therapy. The investigators will analyze peripheral and bone marrow blood samples of the participants, obtained at diagnosis, 15 and 33 days of treatment, about Treg / non Treg cells and interleukin (IL)-2, IL-6, IL-10, and transforming growth factor (TGF) beta levels. By this means, investigators will search response to chemotherapy. Also, investigators will analyze correlation between Treg population-Treg related cytokines with demographic, clinical and laboratory findings of the participants with ALL at these certain time points. Additionally, the investigators will compare Treg population and minimal residual disease at 15-33 days of malignity directed therapy. Also investigators will compare these Treg-Treg related cytokines obtained from the participants with ALL and a healthy children control group whom are voluntary donors for bone marrow transplantation.

Conditions

  • Pre B ALL
  • Regulatory T Cell

Interventions

DIAGNOSTIC_TEST

Peripheral and bone marrow sampling

We obtained blood from peripheral and bone marrow sampling. Then we analyze Treg population and Treg related cytokines with flow cytometry and ELISA methods.

Sponsors & Collaborators

  • Turkish Society of Hematology

    collaborator OTHER

  • Ankara Children's Health and Diseases Hematology and Oncology Training and Research Hospital

    lead OTHER_GOV

Eligibility

Min Age
1 Year
Max Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-01-31
Primary Completion
2019-01-31
Completion
2019-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03413046 on ClinicalTrials.gov